PRODUCT REVIEW FOR CYCLICAL MASTALGIA

20 January 1992

Reviewing products for managing the pain associated with the menstrual cycle, the UK Consumer's Association's Drug and Therapeutics Bulletin has concluded that where the pain has been present for more than six months and significantly affects the quality of the woman's life, there is little to choose from between bromocriptine, danazol or gamolenic acid in terms of efficacy.

The Bulletin adds, however, that while danazol (marketed in the UK as Danol by Winthrop) gives the most rapid response, patients who respond should stop treatment after six months. And even if the pain recurs, they may not require further treatment.

However, it states that antibiotics are still widely prescribed for the indication, but: "There is no evidence to show that antibiotics help . . . any improvement is likely to occur spontaneously."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight